JP2004505940A - 新規なｎ−（２−フェニル−３−アミノプロピル）ナフトアミド - Google Patents

新規なｎ−（２−フェニル−３−アミノプロピル）ナフトアミド Download PDF

Info

Publication number
JP2004505940A
JP2004505940A JP2002517470A JP2002517470A JP2004505940A JP 2004505940 A JP2004505940 A JP 2004505940A JP 2002517470 A JP2002517470 A JP 2002517470A JP 2002517470 A JP2002517470 A JP 2002517470A JP 2004505940 A JP2004505940 A JP 2004505940A
Authority
JP
Japan
Prior art keywords
alkyl
disorder
halogen
anxiety
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002517470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505940A5 (cg-RX-API-DMAC10.html
Inventor
ピーター・バーンスタイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2004505940A publication Critical patent/JP2004505940A/ja
Publication of JP2004505940A5 publication Critical patent/JP2004505940A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2002517470A 2000-08-04 2001-07-31 新規なｎ−（２−フェニル−３−アミノプロピル）ナフトアミド Pending JP2004505940A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0019008.2A GB0019008D0 (en) 2000-08-04 2000-08-04 Therapeutic compounds
PCT/SE2001/001687 WO2002012168A1 (en) 2000-08-04 2001-07-31 Novel n-(2-phenyl-3-aminopropyl)naphtamides

Publications (2)

Publication Number Publication Date
JP2004505940A true JP2004505940A (ja) 2004-02-26
JP2004505940A5 JP2004505940A5 (cg-RX-API-DMAC10.html) 2008-09-04

Family

ID=9896866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002517470A Pending JP2004505940A (ja) 2000-08-04 2001-07-31 新規なｎ−（２−フェニル−３−アミノプロピル）ナフトアミド

Country Status (17)

Country Link
US (1) US6963011B2 (cg-RX-API-DMAC10.html)
EP (1) EP1307425B1 (cg-RX-API-DMAC10.html)
JP (1) JP2004505940A (cg-RX-API-DMAC10.html)
KR (1) KR20030059089A (cg-RX-API-DMAC10.html)
CN (1) CN1444558A (cg-RX-API-DMAC10.html)
AT (1) ATE293591T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001284568A1 (cg-RX-API-DMAC10.html)
BR (1) BR0112957A (cg-RX-API-DMAC10.html)
CA (1) CA2415467A1 (cg-RX-API-DMAC10.html)
DE (1) DE60110233T2 (cg-RX-API-DMAC10.html)
GB (1) GB0019008D0 (cg-RX-API-DMAC10.html)
IL (1) IL153784A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA03000977A (cg-RX-API-DMAC10.html)
NO (1) NO20030509L (cg-RX-API-DMAC10.html)
NZ (1) NZ523434A (cg-RX-API-DMAC10.html)
WO (1) WO2002012168A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200300218B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486842T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
AU2003226149A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
SE0201938D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New process
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
CA2740970A1 (en) 2008-10-21 2010-04-29 Oregon Health & Science University Naphthamides as anticancer agents
CN116102514B (zh) * 2023-01-17 2024-03-15 河南省锐达医药科技有限公司 一类萘酰胺类化合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500029A (ja) * 1986-10-02 1990-01-11 シエーリング　アクチエンゲゼルシヤフト アリール‐ｎ‐アミノアルキル‐４‐（スルホンアミド）ベンズアミド、抗不整脈剤及びその組成物
JPH03246257A (ja) * 1989-11-06 1991-11-01 Warner Lambert Co Ａｃａｔ阻害剤
JPH04217652A (ja) * 1990-03-09 1992-08-07 F Hoffmann La Roche Ag 酢酸誘導体、その製造法、それを含む製薬調製剤、及びその製薬調製剤製造への利用
JP2002526527A (ja) * 1998-10-07 2002-08-20 アストラゼネカ・アクチエボラーグ タキキニン受容体拮抗剤としてのナフタレンカルボキシアミド
JP2002542281A (ja) * 1999-04-27 2002-12-10 サノフィ−サンテラボ あらゆる気分障害、適応障害または不安−抑うつ混合障害の治療または予防に有用な医薬の調製のためのサレドゥタントおよび医薬として許容されるその塩類の使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907571D0 (en) * 1999-04-06 1999-05-26 Zeneca Ltd Compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500029A (ja) * 1986-10-02 1990-01-11 シエーリング　アクチエンゲゼルシヤフト アリール‐ｎ‐アミノアルキル‐４‐（スルホンアミド）ベンズアミド、抗不整脈剤及びその組成物
JPH03246257A (ja) * 1989-11-06 1991-11-01 Warner Lambert Co Ａｃａｔ阻害剤
JPH04217652A (ja) * 1990-03-09 1992-08-07 F Hoffmann La Roche Ag 酢酸誘導体、その製造法、それを含む製薬調製剤、及びその製薬調製剤製造への利用
JP2002526527A (ja) * 1998-10-07 2002-08-20 アストラゼネカ・アクチエボラーグ タキキニン受容体拮抗剤としてのナフタレンカルボキシアミド
JP2002542281A (ja) * 1999-04-27 2002-12-10 サノフィ−サンテラボ あらゆる気分障害、適応障害または不安−抑うつ混合障害の治療または予防に有用な医薬の調製のためのサレドゥタントおよび医薬として許容されるその塩類の使用

Also Published As

Publication number Publication date
NZ523434A (en) 2004-08-27
US6963011B2 (en) 2005-11-08
AU2001284568A1 (en) 2002-02-18
EP1307425A1 (en) 2003-05-07
IL153784A0 (en) 2003-07-31
BR0112957A (pt) 2003-07-08
US20040014809A1 (en) 2004-01-22
DE60110233T2 (de) 2006-03-09
DE60110233D1 (de) 2005-05-25
WO2002012168A1 (en) 2002-02-14
NO20030509D0 (no) 2003-01-31
MXPA03000977A (es) 2003-06-09
ZA200300218B (en) 2004-06-25
KR20030059089A (ko) 2003-07-07
CA2415467A1 (en) 2002-02-14
GB0019008D0 (en) 2000-09-27
ATE293591T1 (de) 2005-05-15
EP1307425B1 (en) 2005-04-20
CN1444558A (zh) 2003-09-24
NO20030509L (no) 2003-03-24

Similar Documents

Publication Publication Date Title
RU2143425C1 (ru) Производные пиперидина, их соли, способы их получения, фармацевтическая композиция на их основе и промежуточные вещества
US6500818B1 (en) Naphthalenecarboxamides as tachykinin receptor antagonists
EP0865430B1 (en) 3-(4-subst.-piperidinyl-1)-1-(3,4-dichlorophenyl)propyl carbamates and ureas and derivatives as novel neurokinin antagonists
JPH08208606A (ja) 治療用化合物
US6924277B2 (en) Cyclized benzamide neurokinin antagonists for use in therapy
PT808303E (pt) Derivados do acido 5-(4-subst.-piperidinil-1)-3-aril pentanoico como antagonistas de receptor de taquiquinina
EP1137637A1 (en) N-(2-phenyl-4-piperidinylbutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
US6821973B2 (en) Compounds
US6963011B2 (en) N-(2-phenyl-3-aminopropyl)naphthamides
JP4088154B2 (ja) ニューロキニン１拮抗薬
EP1278719B1 (en) Naphthamide neurokinin antagonists for use as medicaments
US6903092B2 (en) Naphthamide neurokinin antagonists for use as medicaments
US7235541B2 (en) Neurokinin antagonists for use as medicaments
HK1059078A (en) Novel n-(2-phenyl-3-aminopropyl)naphtamides
ZA200102658B (en) Naphthalenecarboxamides as tachykinin receptor antagonists.
MXPA01003560A (es) Naftalenocarbxamidas como antagonistas receptores de taquicinina
MXPA01008119A (en) (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080711

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018